The deal and funding database built for biopharma. Curated deal comps, company profiles, pipelines, dedicated analyst support so you do better research faster
San Mateo, CA
Joined January 2017
- Tweets488
- Following249
- Followers460
- Likes100
DealForma retweeted
Are you ready for a new year of partnering? Join Inpart and @DealForma's Chris Dokomajilar to unpack the biopharma dealmaking trends of 2024 and predict the transformations that will emerge in 2025. Reserve your seat: eu1.hubs.ly/H0fGSCm0
#biopharmadealmaking
DealForma retweeted
AI/ML drug discovery companies received $490M in upfront payments in '23 & '24 (thru end of Q3) combined across 110 announced deals. "generating $20.9 billion in value" according to data dealforma.com/ai-ml-drug-dis… from @DealForma h/t @ChrisDoko newsletter. '24 surpasses '23 in deal volume but trails in value
DealForma retweeted
AI/ML-enabled drug discovery venture funding increased in '24—by Q3 '24, 175 rounds secured $5.7B vs. 164 rounds raising $4.4B in '23. Over 2 years, 339 rounds have raised $10.1B reported @dealforma
AI/ML drug discovery companies received $490M in upfront payments in '23 & '24 (thru end of Q3) combined across 110 announced deals. "generating $20.9 billion in value" according to data dealforma.com/ai-ml-drug-dis… from @DealForma h/t @ChrisDoko newsletter. '24 surpasses '23 in deal volume but trails in value
DealForma retweeted
Slide of the Most Active AI-Centric Biotechs (or TechBios) based on $ from licensing deals & platform collaborations between 2010 & 2024 Q1—data from @DealForma @chrisdoko incl in Stifel/@timopler's AI report:
DealForma retweeted
Even in bad "Biotech sentiment", larger Series A rounds (~$61M) happening compared to last few years
jpmorgan.com/content/dam/jpm…
DealForma retweeted
Thanks @ChrisDoko & @DealForma for the rich analysis covering 1H'23. Some takeaways:
- M&A picking-up for late-stage assets (Ph2+); interesting to see how recent FTC & continued IRA uncertainty impacts 2H ‘23
DealForma retweeted
Here's a sneak peek at some of the numbers @ChrisDoko of @DealForma will share with our audience next Tuesday, 17 Jan.
As you can see, the total deal volume and #vcfunding were down significantly in 2022 compared to the 2020 and 2021 dealmaking frenzy.
hubs.li/Q01xtqV30
DealForma retweeted
On Tuesday, 17 January at 10 a.m. EST/4 p.m. CET, tune in with @ChrisDoko, CEO & Founder of @DealForma. Armed with fresh data and cutting analysis, Chris will lead us through his 2022 recap and provide projections for 2023.
hubs.li/Q01wM-FY0
DealForma retweeted
Pfizer, Amgen Bristol-Myers Squibb and other drugmakers have paid up to acquire biotechs with approved or drugs that finished testing to quickly offset revenue threatened by generics wsj.com/articles/drugmakers-… w\ @LCooperReports
DealForma retweeted
Rare disease focused drug developers raised $12.5 billion through the first three quarters of 2022, 32% below the capital they raised during the same period in 2021, according to data gathered by @DealForma and @GlobalGenes. @mdaghbio cruches the numbers.
globalgenes.org/2022/10/20/f…
DealForma retweeted
Total public and private equity and debt of rare disease focused therapeutics developers reached $10 billion YTD through the end of August, a 42% drop from a year ago, according to @GlobalGenes @DealForma Marie Daghlian crunches the numbers.
globalgenes.org/2022/09/21/m…
DealForma retweeted
Boom times for biotech ended abruptly in H1 of 2022, making access to capital increasingly difficult for life sciences therapeutics developers as investment fell 39 percent over the same period a year ago, according to data from @GlobalGenes @DealForma
globalgenes.org/2022/07/20/r…
DealForma retweeted
30-year-old female founder's billion-dollar bet on CRISPR gene editing. Great to see Asian-American woman entrepreneur doing great things! @rfannin @cnbc @mammothbiosci @JohnsHopkinsSPH @charlesbridge @DealForma cnbc.com/2022/03/12/30-year-…
DealForma retweeted
Public and private capital raised by rare disease drug developers dropped 42.4 percent year-to-date compared to the same period in 2021, according to data from @DealForma and @GlobalGenes. @mdaghbio crunches the numbers.
globalgenes.org/2022/06/14/r…
DealForma retweeted
Sign up now! Free registration open to everyone (deadline midnight tonight). Been pulling data and analyses all weekend from @BioCentury , @SVB_Financial, @DealForma and several IB reports to provide ‘state of the industry’ metrics! @thebiotechclub @thebiotechclub @BiotechCH
Today (April 10th) at 11:59 PM ET is the deadline to register for this keynote lecture by @cngarabedian from @xontogeny. This event is open to everyone so if interested please register! We look forward to seeing you all tomorrow April 11th from 5:30-7:00 PM ET for the lecture!
DealForma retweeted
Our numbers czar, DealForma’s Chris Dokomajilar, crunched the stats for the first 3 months of the year and found plenty of downdrafts all around, with just a couple of silver linings to look at.
endpts.com/the-good-the-bad-…
DealForma retweeted
#4 is from @ChrisDoko
The 2022 top 100 biopharma investors: A look back on boom times
endpts.com/the-2022-top-100-…